Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tedizolid phosphate for ABSSSI in children (0-12 years)
NCT03176134Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2019
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, single-blind trial of tedizolid in acute bacterial skin and skin structure infection (ABSSSI) (8 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experienced an Adverse Event at 35 days, Number of Participants Who Discontinued Study Treatment Due to an AE at 15 days and 1 more. Started Jan 2019; status: completed.
02
Drugs
tedizolid
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on NCT03176134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03176134.